Translational Cancer Research in Multiple Myeloma, with a Focus on Immune Therapies and Novel Agents – “The Bench Behind the Bedside”
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 20 December 2025 | Viewed by 53
Special Issue Editors
Interests: multiple myeloma; hematology; oncology; endotheliopathy; immune therapy
Interests: multiple myeloma drivers; mechanisms of resistance; preclinical modeling; novel therapeutics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Treatment options for patients with multiple myeloma have expanded rapidly over the past decade, with novel agents, combinations and targets continuing to emerge. In particular, therapy for both newly diagnosed and relapsed/refractory multiple myeloma is continuing to be transformed by the increasing range of immune therapies and targeted agents available in our treatment armamentarium. This wealth of treatment approaches is helping improve the feasibility of tailoring and individualizing treatment for patients based on multiple factors, including personal preferences and disease characteristics, and underpinning the latter is our increasing understanding of critical mechanisms in disease pathobiology, the immune microenvironment, and treatment sensitivity and resistance, as well as factors of importance in optimizing treatment sequencing.
This Special Issue will provide a forum for discussing and sharing new insights into these translational aspects of myeloma therapies, i.e., the research from the ‘bench’ that is driving and informing our success at the ‘bedside’. The focus will be on translational topics related to current and emerging immune therapies–including monoclonal antibodies, antibody–drug conjugates, chimeric antigen receptor (CAR) T-cell therapies, and bispecific antibodies – as well as established and emerging novel targeted therapies such as selinexor, the CELMoDs and novel protein degraders and PROTACs, new peptide-drug conjugates and BCL-2 inhibitors, and inhibitors of new targets such as p300, PERK, IRF4, and epigenetic regulation mechanisms.
We welcome both original research articles and reviews on topics in the above fields. Thank you for your interest in this Special Issue; we look forward to receiving your contributions.
Dr. Paul G. Richardson
Dr. Constantine S. Mitsiades
Dr. Shonali Midha
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- multiple myeloma
- immune microenvironment
- signaling pathways
- therapeutic targets
- immune effector cell therapies
- monoclonal antibodies
- targeted agents
- mechanisms of action
- resistance mechanisms
- treatment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
